Figure 6 — The prognosis, chemotherapy and immunotherapy efficacy of the SUMOylation pathway signature and the role of UBA2 in lung adenocarcinoma

Research Paper|Volume 16, Issue 5|pp. 4378–4395

The prognosis, chemotherapy and immunotherapy efficacy of the SUMOylation pathway signature and the role of UBA2 in lung adenocarcinoma

Back to articleFigure 6(6 of 8)

100%

Figure 6.The prognostic value of SUMOPS for ICI treatment. (A–C) Scores of (A) TIDE, (B) T cell dysfunction and (C) T cell exclusion in different SUMOPS subtypes. (D) Box plots illustrating the relationships between SUMOPS subtypes and the expression of immune checkpoints. ^*p < 0.05; ^**p < 0.01, ^***p < 0.001.